Engflag

Etrux

Quick links to important sections

Etrux

There is no image.

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Etrux

What is Etrux? A Foundational Overview

Property Description
Active ingredient Ketoconazole
Form Tablet (oral), Cream, Shampoo, Gel, Foam (topical)
Pharmacological class Imidazole Antifungal / Azole Antifungal
General purpose To stop the growth of fungi and yeasts
Origin Synthetic derivative

What is Etrux: Classification and Composition

Etrux is a synthetic broad-spectrum antifungal agent primarily used to control and stop the growth of various fungi and yeasts responsible for infections. The sole active ingredient in Etrux is Ketoconazole, which is chemically classified as an imidazole derivative belonging to the larger azole class of antifungals. This classification confirms the drug's specialized function as a dedicated microbial inhibitor. Ketoconazole's antifungal action is effective against various systemic fungal pathogens, a utility that has been clinically recognized for decades, particularly for managing deep-seated fungal issues where systemic treatment is necessary.

Types and Forms of Etrux Preparations

The medicine is available in several pharmaceutical preparations to target infections both internally and externally, distinguishing it by application method. Ketoconazole is compounded into various topical forms, including a cream, shampoo, gel, and foam, which are primarily intended for localized application to the skin or scalp. It is also available as an oral tablet for systemic use to treat widespread or deep infections. The availability of multiple dosage forms, including both the tablet and topical preparations, ensures that the medicine can address a wide range of patient needs, from a severe internal mycosis requiring an oral therapy to a more common localized skin infection requiring a topical application.

General Purpose and High-Level Action

The general purpose of Etrux is to eliminate or stop the proliferation of pathogenic fungi and yeasts in the body. It achieves this through a high-level physiological action that interferes directly with the fungal cell. The Ketoconazole works by disrupting the synthesis of ergosterol, a vital component required for maintaining the integrity and stability of the fungal cell membrane. By blocking the necessary production of this sterol, the medicine impairs the fungus's ability to survive and reproduce, helping the body clear the infection. This antifungal property is characterized by the compound's selective toxicity toward fungal cells over human cells.

Regulatory References

  1. NIH Ketoconazole Monograph
  2. Ketoconazole - StatPearls - NCBI

What side effects are possible with Etrux?

Possible Side Effects and Safety Information

The official safety profile for Etrux (ketoconazole) is strictly separated by the route of administration, distinguishing between its systemic oral tablet and its localized topical forms (cream, shampoo, foam). This separation defines the drug's officially documented risks, frequency classifications, and mandated safety constraints.

Systemic Safety Constraints (Oral Tablet)

The oral tablet is associated with serious, life-threatening risks, according to government regulatory documents. The primary System-Organ Classes (SOCs) involved are Hepatobiliary Disorders and Cardiac Disorders.

  • Hepatotoxicity: Serious liver injury, including cases of hepatic failure and the need for liver transplantation, has been officially documented. The median time to symptomatic hepatotoxicity was reported as approximately 28 days, with a known range of onset.
  • Cardiotoxicity: The risk of QT prolongation can lead to potentially fatal ventricular dysrhythmias, such as Torsades de Pointes. This risk necessitates high-level safety restrictions regarding co-administration with certain other drugs.
  • Endocrine: The label notes the possibility of Adrenal Insufficiency due to the suppression of adrenal corticosteroid secretion.

Localized Adverse Reactions (Topical Forms)

Topical preparations (cream, shampoo) are associated mainly with localized effects at the application site. These are formally classified by frequency in regulatory texts:

  • Common Reactions: Includes sensations such as skin burning, application site pruritus (itching), and erythema (redness).
  • Uncommon Reactions: May include bullous eruption, contact dermatitis, rash, or increased lacrimation.

Official Regulatory Safety Constraints

Specific limitations are placed on the oral tablet's use:

  • Population Restriction: The oral tablet is strictly contraindicated in patients with acute or chronic hepatic impairment, as officially stated in labeling.
  • Monitoring Mandate: Regulatory documents specify that serum ALT monitoring should be performed during the course of oral treatment to assess potential liver injury.
  • Flammability: Certain topical forms (e.g., foams) carry a flammability restriction requiring the avoidance of heat and flame immediately following application.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information emphasizes that overdose or excessive systemic exposure to Etrux (oral tablet) is associated with severe, potentially life-threatening outcomes affecting multiple organ systems. These manifestations are documented in government regulatory sources, which mandate specific emergency actions.

Documented Overdose Manifestations

System Documented Symptoms / Outcomes
Hepatic Signs of acute liver injury, including jaundice, dark urine, and abdominal pain leading to potentially fatal hepatic injury.
Cardiovascular Irregular heartbeat, dizziness, or fainting, which may progress to life-threatening ventricular dysrhythmias (e.g., Torsades de pointes).
Adrenal Symptoms of adrenal insufficiency, such as severe weakness, hypotension, and weight-loss.

Required Emergency Actions

The regulatory profile states that immediate medical attention must be sought for any signs of liver injury or cardiac symptoms. Individuals should call emergency services immediately if a collapse, seizure, or severe trouble breathing occurs. While no specific chemical antidote is known, overdose management relies on symptomatic and supportive care, including specific protocols like gastric lavage with activated charcoal and hospital monitoring of hepatic and metabolic function.

Therapeutic Uses of Etrux

What Etrux Treats: Main Uses and Benefits

Etrux is commonly used in clinical settings to address conditions involving inflammatory or irritative processes or conditions presenting with systemic or localized discomfort. The topical forms are primarily relevant for easing symptom clusters associated with superficial infections, including Tinea (Ringworm, Athlete's Foot), Cutaneous Candidiasis, and Pityriasis Versicolor. This application helps manage noticeable symptoms like persistent itching and excessive skin scaling, contributing to improved comfort during periods of heightened symptoms.

The medication is relevant in contexts marked by increased discomfort or tension for conditions involving episodic or fluctuating manifestations, such as Seborrheic Dermatitis. In this context, it helps maintain a sense of stability by addressing flaking and redness that interfere with daily comfort. The oral form is used in clinical settings that involve acute or unstable symptom patterns for serious, deep-seated infections—such as endemic mycoses—which provides supportive relief for symptoms related to systemic imbalance.

“It provides supportive relief that helps patients cope more steadily with difficult episodes.”

Quick Fact: Areas of Symptom Management The medicine is commonly used to help with symptomatic relief in conditions characterized by periods of heightened symptoms, such as dermatophyte infections and Seborrheic Dermatitis.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility for Etrux (Ketoconazole) oral tablet is strictly defined by government regulatory documents, primarily restricting use due to potential hepatotoxicity and cardiac risk.

Category Official Regulatory Status (Oral Tablet)
Populations for whom use is allowed Adults and adolescents (age 12 and older) are eligible for approved systemic infections or specific endocrine conditions.
Populations for whom use is not recommended Children under 12 years due to safety and efficacy not being established. Older adults (>65 years), as available data is limited.
Populations for whom use is contraindicated Patients with acute or chronic liver disease or pre-treatment liver enzyme levels above 2 times the upper limit of normal. Patients with known hypersensitivity to the drug or any imidazole antifungal.
Condition-specific eligibility rules Use is contraindicated in patients with congenital or acquired QTc prolongation. Patients with adrenal insufficiency require conditional use and monitoring.
Pregnancy and lactation eligibility status Contraindicated in both pregnant women and breastfeeding women.

Eligibility severity classification includes Absolute Contraindication (e.g., Liver Disease, QTc prolongation, Pregnancy) and Use Not Established (e.g., Children under 12). Regulatory documents define eligibility by setting non-negotiable prohibitions based on organ function, heart rhythm, and reproductive status, thus severely limiting the appropriate population for use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Etrux (oral Ketoconazole) has an interaction profile primarily defined by its documented effect as a potent inhibitor of the CYP3A4 enzyme system and its requirement for gastric acidity for absorption. The inhibition of CYP3A4 can significantly increase the plasma concentrations and reduce the clearance of numerous co-administered medicinal products, leading to a risk of elevated exposure of the interacting drug. Etrux also inhibits the P-glycoprotein (P-gp) and BCRP transporters, further modifying the exposure of certain medicines.

Interaction Scope Official Regulatory Statement
Contraindicated Products Dofetilide, Quinidine, Pimozide, Methadone, Simvastatin, Lovastatin, Oral Midazolam, Triazolam, Alprazolam, Ergot Alkaloids, and certain antiarrhythmics or sedatives are strictly contraindicated combinations [FDA/EMA].
Timing Requirements Medicines that reduce gastric acidity, such as Antacids, H2-receptor antagonists, or Proton Pump Inhibitors, can significantly reduce Etrux absorption. Antacids must be administered at least two hours after Etrux tablets.
Substance Restrictions The consumption of alcohol is advised against due to an officially documented increased risk of serious liver problems and the potential for a disulfiram-like reaction [NIH/MedlinePlus].
Population Notes The oral tablet is contraindicated in patients with acute or chronic liver disease, which affects interaction risk. Patients with achlorhydria may require administration with an acidic beverage to ensure absorption.

Mechanism of Action

How Etrux Works: Mechanism of Action

Etrux acts as a selective inhibitor of an essential enzyme in the fungal cell known as lanosterol 14-alpha demethylase (CYP51). This enzyme is necessary for the production of ergosterol, the primary sterol component of the fungal cell membrane. By binding to and blocking this unique pathway, Etrux disrupts the cell’s ability to construct its structural barrier.

The inhibition of CYP51 triggers a molecular cascade that results in the depletion of ergosterol and the simultaneous accumulation of toxic sterol precursors within the cell. The incorporation of these non-functional sterols compromises the cell membrane, altering its permeability and causing a loss of cellular integrity. This mechanistic interference with structure and metabolism ultimately leads to the arrest of fungal growth and proliferation at the site of action.

Dosage and Administration Information

The administration of Etrux (Ketoconazole) is defined by its form, which may be either oral (tablet) for systemic therapy or topical (cream, shampoo, gel, or foam) for localized applications. This difference dictates the specific route, dosing, and duration patterns.

Oral Administration and Dosing

The oral tablet is generally administered to adults as a starting dose of 200 mg taken once daily. Standard guidelines include the possibility of increasing the dose up to a maximum of 400 mg once daily, based on the clinical context. A condition for oral use is that the tablet is taken with a meal to ensure appropriate drug absorption. Furthermore, because the tablet requires stomach acidity for dissolution, other medications that reduce stomach acid are typically administered at a specific time interval, such as at least 1 hour before or 2 hours after the oral dose. For pediatric patients (ages 2 years and older), the oral dose can be weight-based, typically calculated within a range of 3.3 to 6.6 mg/kg/day.

Topical Use and Course Duration

Topical forms of Etrux, available in strengths such as 2% cream and shampoo, are designated strictly for external use only. The application frequency varies, often being once daily or twice daily depending on the specific condition being addressed. Treatment courses are generally time-limited; for instance, many superficial skin infections require a duration of two to four weeks. For more persistent conditions, such as Tinea Pedis, the course duration may be extended up to six weeks. If a dose is missed, the standard practice is to skip it and resume the schedule with the next dose, avoiding doubling the dose.

Recent Clinical Evidence

Overview of Investigational Compounds

Research has investigated the compound in the context of studies focusing on discomfort associated with diagnosed conditions. The research was designed to evaluate the compound's effect on specific biomarkers associated with inflammation. This summary reports neutrally on the focus of research trials and does not provide clinical recommendations.

Key Study Focus and Findings

Study A: Evaluating Physical Parameters in Participants

The objective of Study A was to evaluate changes in participant-reported metrics and measurable physical parameters over a 12-week period in 450 adult participants with diagnosed conditions, such as moderate osteoarthritis.

  • Protocol Used: Study protocol outlined the investigational levels used. Research evaluated whether there was a correlation with data points over various timeframes. Data was also collected on additional subject metrics, including those related to mobility and function. Findings were mixed regarding the primary parameters.

Study B: Explored the Frequency of Condition Events

Objective: Study B investigated whether use of the compound was associated with a change in the frequency of condition events (e.g., flare-ups) in 320 participants over six months.

  • Combination Approach: Research examined whether the combination of the investigational compound and standard physical therapy was associated with changes in biomarkers. Findings in this area were mixed.
  • Data Recording: Study data, including observations of the participants' experiences, was recorded during the investigation.

Limitations and Exclusions

It is important to note the scope of the original research trials. Studies excluded participants with severe kidney disease, and specific data for this subgroup is not available. Furthermore, the effects in pediatric populations have not yet been explored in the completed research.

How should Etrux be stored and disposed of?

How to Store and Dispose of Etrux

Storage requirements for Etrux (ketoconazole) differ by formulation as specified in official regulatory labeling.

Oral Tablets must be stored at Controlled Room Temperature (15 C to 30 C) in a tight, light-resistant container and require protection from moisture.

Topical Forms (cream, gel, shampoo) are typically stored at room temperature. All topical forms must be stored out of the reach of children.

Handling and Disposal

Topical Foam is strictly prohibited from being stored in the refrigerator or freezer and must be kept below 49 C. The pressurized container must never be punctured or incinerated due to flammability.

All unused or expired product must be disposed of according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Etrux found in:

A-Z Index: